The original version of this article failed to report that Stratagene posted a decline in fourth-quarter 2006 revenue because of one-time settlement income received from Cambridge Antibody Technology during the fourth quarter of 2005.
 
NEW YORK (GenomeWeb News) — Stratagene yesterday said fourth-quarter revenues fell 57 percent as R&D spending dipped 18 percent and profit increased 350 percent as the company settled an expensive patent-litigation suit with Third Wave Technologies.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.